Predicted protein targets (top 14)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MAPT | P10636 | 4/20 | 0.43 |
| ▸ | MAPK14 | Q16539 | 4/20 | 0.42 |
| ▸ | HTT | P42858 | 1/20 | 0.39 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.35 |
| ▸ | GSR | P00390 | 1/20 | 0.33 |
| ▸ | TXNRD1 | Q16881 | 1/20 | 0.33 |
| ▸ | BRAF | P15056 | 6/20 | 0.33 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.33 |
| ▸ | LMNA | P02545 | 1/20 | 0.33 |
| ▸ | HPGD | P15428 | 1/20 | 0.33 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.33 |
| ▸ | FGFR4 | P22455 | 1/20 | 0.32 |
| ▸ | TGFBR1 | P36897 | 1/20 | 0.32 |
| ▸ | MTOR | P42345 | 1/20 | 0.32 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL3992567 | 0.94 | MAPK14 (0.45) | MAPTMAPK14KMT2ABRAFKDM4E | |
| SCHEMBL3992075 | 0.85 | MAPK14 (0.51) | MAPTMAPK14KMT2ABRAFLMNA | |
| SCHEMBL4067180 | 0.82 | MAPK14 (0.49) | MAPTMAPK14KMT2A | |
| SCHEMBL4064671 | 0.82 | PRKCQ (0.45) | MAPK14 | |
| SCHEMBL4067901 | 0.80 | BRAF (0.38) | MAPK14KMT2ABRAF | |
| SCHEMBL3989359 | 0.79 | MAPK14 (0.57) | MAPK14 | |
| SCHEMBL3997933 | 0.79 | MAPK14 (0.51) | MAPK14 | |
| SCHEMBL3992174 | 0.78 | KMT2A (0.36) | MAPTKMT2AKDM4ELMNAHPGD | |
| SCHEMBL3995132 | 0.78 | MAPT (0.62) | MAPTHTTKMT2AGSRTXNRD1 | |
| SCHEMBL4067386 | 0.77 | MAPK14 (0.53) | MAPK14KMT2ABRAF |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20090318443-A1 | KINASE INHIBITORS | BONJOUKLIAN ROSANNE | 2009-12-24 | — | — | US | disclosed |
| US-7582652-B2 | Suppression cytokines, tumor necrosis factor; melanoma | ELI LILLY AND COMPANY (US) | 2009-09-01 | — | — | US | disclosed |
| EP-1713805-B1 | KINASE INHIBITORS | LILLY CO ELI (US) | 2009-06-10 | — | — | EP | disclosed |
| US-20090036445-A1 | KINASE INHIBITORS | ELI LILLY AND COMPANY | 2009-02-05 | — | — | US | disclosed |
| EP-1713805-A1 | KINASE INHIBITORS | ELI LILLY AND COMPANY (US) | 2006-10-25 | — | — | EP | disclosed |
| WO-2005075478-A1 | KINASE INHIBITORS | ELI LILLY AND COMPANY (US) | 2005-08-18 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20090036445-A1 | KINASE INHIBITORS | MAP3K20, MAP3K19, MAP3K1 | MAPT 2655/4885MAPK14 174/4885HTT 4681/4885 |
| US-20090318443-A1 | KINASE INHIBITORS | MAP3K20, MAP3K19, MAP3K1 | MAPT 2655/4885MAPK14 174/4885HTT 4681/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.